Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06756321 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 3, 2025 (before its estimated March 18, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This study is a single-center, open-label clinical trial of single-dose of CAR T-cells in subjects with relapsed/refractory hematologic malignancy.
Trial Details
NCT Number NCT06756321
Lead Sponsor Affiliated Hospital of Nantong University
Collaborators: Shanghai First Song Biotechnology Co., LTD
Conditions
(from sponsor)		 Relapsed/refractory Lymphoma, Relapsed/Refractory Leukemia
Related terms Leukemia, Lymphoma
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov